ArticleArchives of toxicology2025
Exposure risk assessment of di(2-ethylhexyl)phthalate (DEHP) using human population pharmacokinetic modeling of DEHP and its major in vivo metabolites.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Translating human biomonitoring data into quantitative exposure and risk estimates for chloromethylisothiazolinone and methylisothiazolinone using a population pharmacokinetic model.Archives of toxicology · 2026Article
- Analysis of in vitro profiling data of cosmetic ingredients within the Tox21 10K compound library for bioactivity and potential toxicity.BMC pharmacology & toxicology · 2026Article
- [Development and Application of a Method for Determining 33 Aromatic Primary Amines in Medical-Grade Thermoplastic Polyurethane by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Network Toxicology Reveals the Mechanisms of the Plasticizer Metabolite MECPP in Metabolic Diseases.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Di(2-ethylhexyl)phthalate (DEHP) is widely used as a plasticizer and is associated with potential adverse health effects, including endocrine disruption and organ toxicity. Accurate assessment of DEHP exposure risks requires robust pharmacokinetic models capable of capturing inter-individual variability and integrating human biomonitoring data. This study aimed to develop and validate a population pharmacokinetic model for DEHP and its major metabolites, mono(2-ethylhexyl)phthalate (MEHP), 2-ethyl-5-hydroxy-hexylphthalate (5-OH MEHP), and 2-ethyl-5-oxo-hexylphthalate (5-Oxo MEHP), to quantitatively assess DEHP exposure risks in human populations. Clinical data from DEHP-d
Indexed as
Identifiers
40372421What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.